Clinical Trial: Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
Sponsor and Collaborators
H. Lee Moffitt Cancer Center and Research Institute
Millennium Pharmaceuticals, Inc.
Contact: Christine McIsaac, RN
Melissa Alsina, MD H. Lee Moffitt Cancer Center and Research Institute
Next post in Multiple Myeloma Clinical Trials
Log in to continue reading this article.
Don’t miss out on today’s top content on Oncology Nurse Advisor. Register for free and gain unlimited access to:
- Clinical Updates
- Evidence-Based Guidance
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
Want to read more?
Please login or register first to view this content.